Mid-term Impact of Bariatric Surgery on Cardiac Structure and Function



Impacto de la cirugía bariátrica a medio plazo en la estructura y la función del corazón

To the Editor,

Obesity is an increasingly prevalent cardiovascular risk factor.¹ It implies a hemodynamic overload, leading to functional anatomical changes in the heart, with ventricular hypertrophy and systo-diastolic dysfunction.²

The most effective treatment is bariatric surgery, which has a cardioprotective effect, improving ventricular geometry and function.³

We analyzed medium-term structural and functional changes in the hearts of patients with morbid obesity who had bariatric surgery.

This was a prospective study of patients with morbid obesity followed up in the Obesity Unit and referred for bariatric surgery between January 2010 and June 2014. Patients with coronary artery disease, valve disease, cardiomyopathies, or congenital heart disease were excluded.

Patients had an echocardiogram 1 month before and 6 months after surgery. The assessments were performed by an experienced examiner, who did not know if it was the first or second study.

For the left ventricular (LV) geometry study, M-mode was used to obtain ventricular diameters, wall thickness, and relative wall thickness (RWT):

RWT = $(2 \times \text{posterior wall}) / \text{LV end-diastolic diameter}$

Left ventricular mass was calculated according to the Devereux formula, with height indexed to the power of 2.7 to minimize interference of obesity.⁴

An LV mass index (LVMI) \geq 51 g/m^{2.7} constituted hypertrophy. Patients were classified into 4 geometric patterns, according to RWT and LVMI:

1. Normal, RWT < 0.45 and LVMI < 51 g/m^{2.7}.

2. Concentric remodeling, RWT \ge 0.45 and LVMI < 51 g/m^{2.7}.

3. Eccentric hypertrophy, RWT < 0.45 and LMVI $\geq 51~g/m^{2.7}.$

4. Concentric hypertrophy, RWT \geq 0.45 and LMVI \geq 51 g/m^{2.7}.

Geometric pattern was considered an ordinal qualitative variable, with concentric hypertrophy being the least favorable pattern, followed by eccentric hypertrophy, and concentric remodeling.

Evaluation of LV systolic function was based on ejection fraction from the Teichholz method, and tissue Doppler analysis of systolic mitral annular displacement. Evaluation of LV diastolic function was based on pulsed Doppler of mitral flow and tissue Doppler of diastolic mitral annular displacement. Patients were classified into 3 groups according to diastolic function⁵: a) normal filling, b) impaired relaxation, and c) pseudonormal filling.

For statistical analysis, the statistics package STATA v. 12.1 was used. Continuous variables were expressed as mean \pm standard deviation, and categorical variables were expressed as absolute values and percentages. Changes in continuous quantitative variables were analyzed with the paired Student *t* test, and changes in ordinal qualitative variables were analyzed with the Wilcoxon signed rank test.

Thirty-two patients completed the study. They had a mean age of 45.1 years, and 87.5% were women. Associated comorbidities consisted of hypertension in 56.3%, diabetes in 34.4%, dyslipidemia in 21.9%, and smoking in 28.1%. Mean body mass index before surgery was 47.3.

At 6 months postsurgery, there was a loss of $30.2\% \pm 9.2\%$ of baseline body weight, improved metabolic profile, and a reduction in

Table

Patient Clinical and Echocardiographic Characteristics Before and After Surgery (n = 32)

	One month before surgery	Six months after surgery	Р
LVMI ^{2.7}	$\textbf{50.8} \pm \textbf{14.7}$	$\textbf{49.8} \pm \textbf{15.8}$.77
Systolic BP, mmHg	136.17	121.17	.001
Diastolic BP, mmHg	81.17	77.55	.26
Number of antihypertensive medications	1.17 ± 0.71	$\textbf{0.67}\pm\textbf{0.6}$.008
HR, bpm	72.1	69.7	.79
LA diameter, mm	41.39	40.9	.62
LVEF, %	$\textbf{68.6} \pm \textbf{1.4}$	$\textbf{69.1} \pm \textbf{1.9}$.9
S' velocity on TDI	$\textbf{9.4}\pm\textbf{0.5}$	$\textbf{8.8}\pm\textbf{0.3}$.1
RWT, mm	$\textbf{0.4}\pm\textbf{0.1}$	$\textbf{0.3}\pm\textbf{0.05}$.03
LVEDD, mm	$\textbf{49.4} \pm \textbf{7.4}$	$\textbf{52.8} \pm \textbf{5.5}$	< .01
LVESD, mm	$\textbf{29.8} \pm \textbf{5.6}$	$\textbf{31.0} \pm \textbf{5.1}$.27
Septum, mm	$\textbf{10.1} \pm \textbf{1.4}$	$\textbf{8.9}\pm\textbf{1.4}$	< .001
Posterior wall, mm	$\textbf{9.9}\pm\textbf{1.6}$	8.9 ± 1.4	.01
E/A ratio	$\textbf{0.9}\pm\textbf{0.3}$	1.3 ± 0.3	< .001
E/E' ratio	$\textbf{8.2}\pm\textbf{0.34}$	$\textbf{9.4}\pm\textbf{0.5}$.01
Deceleration time, ms	$\textbf{230.3} \pm \textbf{10.1}$	$\textbf{184.8} \pm \textbf{11.2}$.03
Normal diastolic function, %	28.1	68.8	.002
Normal geometric pattern	9 (28.1)	19 (59.4)	
Concentric remodeling	6 (18.8)	1 (3.1)	- 007
Eccentric hypertrophy	13 (40.6)	12 (37.5)	.007
Concentric hypertrophy	4 (12.5)	0	

BP, blood pressure; HR, heart rate; LA, left atrium; LVEDD, left ventricular enddiastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVMI^{2.7}, left ventricular mass index (LV mass in grams, divided by height in meters to the power of 2.7); RWT, relative wall thickness; TDI tissue Doppler imaging.

the number of antihypertensive medications (Table). The echocardiographic findings were as follows:

• Structural findings: baseline mean LV diameters were normal. Mean RWT was 0.41, and mean LVMI was 50.8 kg/m^{2.7}. Baseline geometric pattern: 28.1% of patients had a normal pattern. Of those with abnormal ventricular geometry, more than 50% had hypertrophy, with eccentric hypertrophy being the most common. At 6 months postsurgery, the LV end-diastolic diameter had increased and there was a reduction in wall thickness and RWT.



Figure. Changes in geometric pattern before and after surgery.

There was no significant change in LVMI. At the end of the study, the geometric pattern showed significant improvement (Figure).

• Functional changes: LV systolic function was normal in all patients and did not change. Regarding LV diastolic function, 28% of patients had normal filling, almost 69% had an impaired relaxation pattern, and 3% had pseudonormal filling. At the end of the study, E wave velocity had increased, E/A ratio had decreased, and deceleration time had shortened. At the end of follow-up, LV diastolic function had significantly improved, with 69% of patients showing normal filling.

A high percentage of our patients showed some type of ventricular remodelling, the most common type being eccentric hypertrophy, which concurs with reports by other authors.⁶ Unlike other studies, the improved geometric pattern in our patients was fundamentally due to a marked reduction in RWT, with no significant changes in LVMI. This improvement in ventricular geometry was accompanied by normalization of diastolic function in more than half of the patients.

Verónica Hernández Jiménez,^{a,*} Jesús Saavedra Falero,^a M. Teresa Alberca Vela,^a Paloma Iglesias Bolaños,^b Susana Monereo Mejías,^b and Juan Carlos Ruíz de Adana^c

^aServicio de Cardiología, Hospital Universitario de Getafe, Getafe, Madrid, Spain

^bServicio de Endocrinología, Hospital Universitario de Getafe, Getafe, Madrid, Spain

Left Atrial Appendage Occlusion With the New Amulet[™] Device: Feasibility, Safety and Short-term Efficacy

Cierre percutáneo de la orejuela izquierda con el nuevo dispositivo AmuletTM: factibilidad, seguridad y eficacia a corto plazo

To the Editor,

Percutaneous occlusion of the left atrial appendage (LAA) is an alternative to oral anticoagulation therapy for the prevention of ischemic stroke in patients with nonvalvular atrial fibrillation.¹

Currently, the 2 devices most frequently used for percutaneous LAA occlusion are the WatchmanTM system (Boston Scientific) and the AmplatzerTM Cardiac Plug (St. Jude Medical). A recently designed second generation of the AmplatzerTM Cardiac Plug, the AmuletTM device (St. Jude Medical), introduces modifications to facilitate device implantation and reduce complications.²

The AmuletTM device obtained the European Economic Area CE mark in January 2013, and in February 2013 the device received a restricted launch in selected centers, producing good results.^{2,3} However, difficulties were encountered with the release of a new internal delivery cable, forcing the company to halt distribution in July of the same year. After modification of the cable, the AmuletTM device was relaunched in a restricted setting in October 2014, and to our knowledge, there has been no published report to date on its safety and short-term efficacy.

The study included all consecutive patients undergoing percutaneous LAA with the AmuletTM device at 2 centers between October and December 2014. Procedures were performed as described,³ and clinical and echocardiographic follow-up was scheduled for 2 to 3 months after the procedure.

A total of 20 patients were included; population and procedure characteristics are shown in the Table.

^cServicio de Cirugía General y Digestivo, Hospital Universitario de Getafe, Getafe, Madrid, Spain

* Corresponding author: *E-mail address:* veronicahernandezz@hotmail.com (V. Hernández liménez).

Available online 19 June 2015

REFERENCES

- Valdés S, García-Torres F, Maldonado-Araque C, Goday A, Calle-Pascual A, Soriguer F, et al. Prevalencia de obesidad, diabetes mellitus y otros factores de riesgo cardiovascular en Andalucía. Comparación con datos de prevalencia nacionales. Estudio Di@bet.es. Rev Esp Cardiol. 2014;67:442–8.
- Garza CA, Pellikka PA, Somers VK, Sarr MG, Seward JB, Collazo-Clavell ML, et al. Major weight loss prevents long-term left atrial enlargement in patients with morbid and extreme obesity. Eur J Echocardiogr. 2008;9:587–93.
- Luaces M, Cachofeiro V, García-Muñoz Najar A, Medina M, González N, Cancer E, et al. Modificaciones anatomofuncionales del corazón en obesidad mórbida. Cambios tras cirugía bariátrica. Rev Esp Cardiol. 2012;65:14–21.
- 4. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of of overweight. J Am Coll Cardiol. 1992;20:1251–60.
- Nishimura R, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta stone. J Am Coll Cardiol. 1997;30:8–18.
- 6. Cuspidi C, Rescaldani M, Sala C, Grassi G. Left ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies. J Hypertens. 2014;32:16–25.

http://dx.doi.org/10.1016/j.rec.2015.03.010

Table

Study Population and Procedure Characteristics

Patients, no.	20		
Age, years	77 ± 7		
Men	14 (70)		
Indication for LAA occlusion (contraindication for OAC), %			
Gastrointestinal bleeding	70		
Other	30		
CHA ₂ DS ₂ -VASc score	4.9 ± 1.3		
HAS-BLED score	$\textbf{4.9} \pm \textbf{1.16}$		
Rhythm during implantation			
Sinus rhythm	6 (30)		
AF	14 (70)		
LAA morphology			
Cactus	2 (10)		
Chicken wing	6 (30)		
Windsock	7 (35)		
Cauliflower	5 (25)		
Number of LAA lobes			
1	11 (55)		
2	9 (45)		
Maximum LAA diameter by angiography, mm	19.7 ± 5		
Maximum LAA diameter by TEE, mm	19.9 ± 5.5		
Device size, mm	24.1 ± 5.3		
Successful implants	20 (100)		
Periprocedural complications	0 (0)		

AF, atrial fibrillation; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly [> 65 years], drugs/alcohol concomitantly; LAA, left atrial appendage; OAC, oral anticoagulation therapy; TEE, transesophageal echocardiogram. Values are expressed as no. (%) or mean \pm standard deviation.

ew CrossMark

